JUPITER NEUROSCIENCES, INC.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
JUNS$2.22+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements Of Operations
JUPITER NEUROSCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| For the Three Months Ended · For the Three Months Ended | |||
|---|---|---|---|
| March 31, 2026 · March 31, 2025 | |||
| Product Revenues, net | $18,652 | $ | - |
| Cost of goods sold | 4,362 | - | |
| Gross Profit | $14,290 | $ | - |
| Expenses: | |||
| Research and development | 411,049 | 466,745 | |
| General and administrative | 1,566,241 | 1,071,258 | |
| Total operating expenses | 1,977,290 | 1,538,003 | |
| Operating loss | (1,963,000) | (1,538,003) | |
| Other Income (Expenses): | |||
| Interest income | 18,404 | 10,365 | |
| Gain on change in fair value of convertible notes | 1,282 | - | |
| Interest expense | (118,644) | (1,229) | |
| Total other expenses, net | (98,958) | 9,136 | |
| Net loss | $(2,061,958) | $(1,528,867) | |
| Net loss per common share: | |||
| Basic and Diluted | $(0.06) | $(0.05) | |
| Weighted average number of common shares outstanding: | |||
| Basic and Diluted | 35,255,588 | 33,103,860 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.